Sirolimus 0.4%    (DrugBank: Sirolimus)

1 disease
IDDisease name (Link within this page)Number of trials
158Tuberous sclerosis1

158. Tuberous sclerosis    [ 100 clinical trials,   62 drugs,   (DrugBank: 16 drugs),   35 drug target genes,   115 drug target pathways]
Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 100 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03363763
(ClinicalTrials.gov)
April 12, 20171/12/2017Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis ComplexPhase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open LabelAngiofibroma of Face;Tuberous SclerosisDrug: Sirolimus 0.2%;Drug: Sirolimus 0.4%;Drug: Placebo ointmentAucta Pharmaceuticals, IncNULLRecruiting2 Years18 YearsAll45Phase 2United States;China